Eisai Innovation to Host Virtual Seminar on Its Inaugural Eisai Golden Ticket Competition

MBC BioLabs & Eisai to Present the 2021 Golden Ticket Program

Eisai Innovation, Inc. (EII), an affiliate of Eisai Co., Ltd. the fully integrated pharmaceutical company based in Tokyo, Japan, is partnering with MBC BioLabs to award one Golden Ticket to an innovative life science startup. The winner of Eisai’s Golden Ticket receives one-year free lab space at an MBC BioLabs facility, as well as access to the shared amenities and services provided at MBC BioLabs. They will also have access to scientific and business leaders at Eisai.

To learn more about the Golden Ticket and Eisai, please join the virtual seminar with representatives from EII and Eisai Co., Ltd. on September 15. The seminar will include an overview of the company’s R&D functions, therapeutics and technology focus areas, business, partnering and investment strategy.

Register for Event: September 15, 2021, 3:00pm-4:00pm PST – Online Event
Click REGISTER below, and we’ll email you the Zoom link.






Introducing Our Presenters:

Kazumasa Nagayama
(Chief Strategy Officer, Eisai and Board Chair, Eisai Innovation)

Dr. Takashi Owa
(Oncology Business Group Chief Medicine Creation Officer & Chief Discovery Officer, Eisai)

Teiji Kimura
(Neurology Business Group Chief Discovery Officer, Eisai)

Kappei Tsukahara
(Chief Data Officer, Eisai)

About MBC BioLabs

Learn More About MBC BioLabs

Rent a Bench. Change the World.

We’ve Helped 215 Companies Raise $7B In Funding.

MBC BioLabs is dedicated to helping life-science startups succeed. By renting space as small as a single bench and providing these entrepreneurial scientists with access to millions of dollars of equipment, we allow companies to be fast, focused, and frugal. We now have three sites: one in the Dogpatch neighborhood in San Francisco and two campuses in San Carlos. Each site has a complete molecular biology core facility that allows companies to do experiments on day one, not year one. We have partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission BioCapital. These partnerships provide our entrepreneurs with valuable insights about where to focus their efforts and accelerates the innovation pipeline. Our labs have truly enabled awesome: since our opening in 2013 we have helped launch and grow 230 companies. These companies have brought 54 programs to the clinic, produced 13 approved diagnostics, and raised over $7 billion.

About Eisai Innovation, Inc.

EII is Eisai’s strategic investment organization aspiring to identify synergies between the scientific community and the Eisai network of companies. EII has provided equity investments to early-stage companies which develop cutting-edge drug discovery technologies, novel targets and innovative healthcare solutions. For more information about Eisai Innovation, Inc. please visit www.eisaiinnovation.com.

Learn More About Eisai Innovation

About Eisai

Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan, with approximately 10,000 employees worldwide. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. We strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including Oncology and Neurology. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society’s toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on Twitter (U.S. and global) and LinkedIn (U.S. and EMEA).

Learn More About Eisai